ATE282604T1 - Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten - Google Patents

Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten

Info

Publication number
ATE282604T1
ATE282604T1 AT00989326T AT00989326T ATE282604T1 AT E282604 T1 ATE282604 T1 AT E282604T1 AT 00989326 T AT00989326 T AT 00989326T AT 00989326 T AT00989326 T AT 00989326T AT E282604 T1 ATE282604 T1 AT E282604T1
Authority
AT
Austria
Prior art keywords
tetrahydrocinolines
dihydrobenzothiopyrans
dihydrobenzopyrans
cox
treatment
Prior art date
Application number
AT00989326T
Other languages
English (en)
Inventor
Donald J Rogier Jr
Jeffrey S Carter
John J Talley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22635573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE282604(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE282604T1 publication Critical patent/ATE282604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00989326T 2000-01-03 2000-12-19 Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten ATE282604T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17428100P 2000-01-03 2000-01-03
PCT/US2000/034525 WO2001049675A1 (en) 2000-01-03 2000-12-19 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders

Publications (1)

Publication Number Publication Date
ATE282604T1 true ATE282604T1 (de) 2004-12-15

Family

ID=22635573

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00989326T ATE282604T1 (de) 2000-01-03 2000-12-19 Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten

Country Status (16)

Country Link
US (2) US6822102B2 (de)
EP (1) EP1274700B1 (de)
JP (1) JP2003519221A (de)
AR (1) AR026784A1 (de)
AT (1) ATE282604T1 (de)
AU (1) AU2584001A (de)
CA (1) CA2395795A1 (de)
DE (1) DE60016047T2 (de)
EC (1) ECSP013867A (de)
ES (1) ES2231301T3 (de)
MX (1) MXPA02006617A (de)
PE (1) PE20010995A1 (de)
PT (1) PT1274700E (de)
TW (1) TWI227234B (de)
WO (1) WO2001049675A1 (de)
ZA (1) ZA200205098B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
WO2004032848A2 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
CA2424009A1 (en) 2003-03-28 2004-09-28 Ibm Canada Limited - Ibm Canada Limitee Context-sensitive attributes
GB0407908D0 (en) 2004-04-07 2004-05-12 Univ York Ionic liquids
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006040672A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
PT2593452T (pt) 2010-07-14 2017-04-24 Novartis Ag Compostos heterocíclicos agonistas do receptor ip
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
CN119954759B (zh) * 2025-01-03 2025-10-21 安炎达医药技术(广州)有限公司 一种苯并吡喃类cox-2抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234029A (zh) * 1996-08-27 1999-11-03 盐野义制药株式会社 色烯－3－羚酸衍生物
DE19638484A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation

Also Published As

Publication number Publication date
AR026784A1 (es) 2003-02-26
US20030232844A1 (en) 2003-12-18
MXPA02006617A (es) 2004-09-10
DE60016047T2 (de) 2005-11-03
JP2003519221A (ja) 2003-06-17
WO2001049675A1 (en) 2001-07-12
PT1274700E (pt) 2005-02-28
DE60016047D1 (de) 2004-12-23
US6822102B2 (en) 2004-11-23
PE20010995A1 (es) 2001-09-21
CA2395795A1 (en) 2001-07-12
EP1274700B1 (de) 2004-11-17
EP1274700A1 (de) 2003-01-15
TWI227234B (en) 2005-02-01
US20050010050A1 (en) 2005-01-13
ZA200205098B (en) 2004-03-31
AU2584001A (en) 2001-07-16
ES2231301T3 (es) 2005-05-16
ECSP013867A (es) 2002-09-27

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
MXPA03007816A (es) Calzoncillo desechable y metodo para proporcionar el mismo.
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
FIU20060389U0 (fi) Luusairauksien hoito
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
PL358451A1 (pl) Sposób sterylizacji materiałów biologicznych
DE60224163D1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
ATE282604T1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60328494D1 (de) Verbessertes system zur behandlung der stressbedingten harninkontinenz
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274700

Country of ref document: EP

REN Ceased due to non-payment of the annual fee